Metastatic placental site trophoblastic tumor

L. B. Twiggs, E. Hartenbach, A. K. Saltzman, L. A. King

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Since our publication, which first defined the malignant potential of placental site trophoblastic tumor (PSTT), we have had a keen interest in this rare, unique entity. This histologic entity is noted by its monomorphic population of trophoblast-like cells which are classified as originating in the intermediate trophoblast, These cells contain hymman placental lactogen (HPL), This is in contrast to cytotrophoblastic and syncytiotrophblastic tissues as the histologic, cytologic and immunohistochemical stain characteristics are disparate. Its rarity and the wide spectrum of clinical behavior combined with the lack of sensitivity of serum levels of beta hCG in predicting disease recurrence and spread have lead to anecdotal reports outlining clinical management. Most discerning to the clinician is the high mortality of metastatic placental site trophoblastic tumor. At our institution, we have treated two patients with a metastatic disease with a successful conclusion. The durability of responses is 3 and 8 years. This report will present these patients in detail and define the important characteristics of successful treatment. The use of dose-intensive, multi-agent chemotherapy, early intervention when metastatic disease is discovered, imaging techniques to define disease spread, surgery for localized disease and the use of growth factors, most notably granulocyte colony-stimulating factor (G-CSF), are the fundamentals of clinical care of placental site trophoblastic tumor in patients with metastatic placental site trophoblastic tumor.

Original languageEnglish
JournalInternational Journal of Gynecology and Obstetrics
Volume60
Issue numberSUPPL.1
StatePublished - Dec 1 1998
Externally publishedYes

Fingerprint

Placental Site Trophoblastic Tumor
Trophoblasts
Placental Lactogen
Granulocyte Colony-Stimulating Factor
Intercellular Signaling Peptides and Proteins
Coloring Agents
Recurrence
Drug Therapy
Mortality
Serum
Population

Keywords

  • Malignant trophoblastic disease
  • Placental site trophoblastic tumor
  • Trophoblastic disease
  • Trophoblastic pseudotumor

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Twiggs, L. B., Hartenbach, E., Saltzman, A. K., & King, L. A. (1998). Metastatic placental site trophoblastic tumor. International Journal of Gynecology and Obstetrics, 60(SUPPL.1).

Metastatic placental site trophoblastic tumor. / Twiggs, L. B.; Hartenbach, E.; Saltzman, A. K.; King, L. A.

In: International Journal of Gynecology and Obstetrics, Vol. 60, No. SUPPL.1, 01.12.1998.

Research output: Contribution to journalArticle

Twiggs, LB, Hartenbach, E, Saltzman, AK & King, LA 1998, 'Metastatic placental site trophoblastic tumor', International Journal of Gynecology and Obstetrics, vol. 60, no. SUPPL.1.
Twiggs LB, Hartenbach E, Saltzman AK, King LA. Metastatic placental site trophoblastic tumor. International Journal of Gynecology and Obstetrics. 1998 Dec 1;60(SUPPL.1).
Twiggs, L. B. ; Hartenbach, E. ; Saltzman, A. K. ; King, L. A. / Metastatic placental site trophoblastic tumor. In: International Journal of Gynecology and Obstetrics. 1998 ; Vol. 60, No. SUPPL.1.
@article{c273d713a2f34a36bf7088e889fe4e98,
title = "Metastatic placental site trophoblastic tumor",
abstract = "Since our publication, which first defined the malignant potential of placental site trophoblastic tumor (PSTT), we have had a keen interest in this rare, unique entity. This histologic entity is noted by its monomorphic population of trophoblast-like cells which are classified as originating in the intermediate trophoblast, These cells contain hymman placental lactogen (HPL), This is in contrast to cytotrophoblastic and syncytiotrophblastic tissues as the histologic, cytologic and immunohistochemical stain characteristics are disparate. Its rarity and the wide spectrum of clinical behavior combined with the lack of sensitivity of serum levels of beta hCG in predicting disease recurrence and spread have lead to anecdotal reports outlining clinical management. Most discerning to the clinician is the high mortality of metastatic placental site trophoblastic tumor. At our institution, we have treated two patients with a metastatic disease with a successful conclusion. The durability of responses is 3 and 8 years. This report will present these patients in detail and define the important characteristics of successful treatment. The use of dose-intensive, multi-agent chemotherapy, early intervention when metastatic disease is discovered, imaging techniques to define disease spread, surgery for localized disease and the use of growth factors, most notably granulocyte colony-stimulating factor (G-CSF), are the fundamentals of clinical care of placental site trophoblastic tumor in patients with metastatic placental site trophoblastic tumor.",
keywords = "Malignant trophoblastic disease, Placental site trophoblastic tumor, Trophoblastic disease, Trophoblastic pseudotumor",
author = "Twiggs, {L. B.} and E. Hartenbach and Saltzman, {A. K.} and King, {L. A.}",
year = "1998",
month = "12",
day = "1",
language = "English",
volume = "60",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL.1",

}

TY - JOUR

T1 - Metastatic placental site trophoblastic tumor

AU - Twiggs, L. B.

AU - Hartenbach, E.

AU - Saltzman, A. K.

AU - King, L. A.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Since our publication, which first defined the malignant potential of placental site trophoblastic tumor (PSTT), we have had a keen interest in this rare, unique entity. This histologic entity is noted by its monomorphic population of trophoblast-like cells which are classified as originating in the intermediate trophoblast, These cells contain hymman placental lactogen (HPL), This is in contrast to cytotrophoblastic and syncytiotrophblastic tissues as the histologic, cytologic and immunohistochemical stain characteristics are disparate. Its rarity and the wide spectrum of clinical behavior combined with the lack of sensitivity of serum levels of beta hCG in predicting disease recurrence and spread have lead to anecdotal reports outlining clinical management. Most discerning to the clinician is the high mortality of metastatic placental site trophoblastic tumor. At our institution, we have treated two patients with a metastatic disease with a successful conclusion. The durability of responses is 3 and 8 years. This report will present these patients in detail and define the important characteristics of successful treatment. The use of dose-intensive, multi-agent chemotherapy, early intervention when metastatic disease is discovered, imaging techniques to define disease spread, surgery for localized disease and the use of growth factors, most notably granulocyte colony-stimulating factor (G-CSF), are the fundamentals of clinical care of placental site trophoblastic tumor in patients with metastatic placental site trophoblastic tumor.

AB - Since our publication, which first defined the malignant potential of placental site trophoblastic tumor (PSTT), we have had a keen interest in this rare, unique entity. This histologic entity is noted by its monomorphic population of trophoblast-like cells which are classified as originating in the intermediate trophoblast, These cells contain hymman placental lactogen (HPL), This is in contrast to cytotrophoblastic and syncytiotrophblastic tissues as the histologic, cytologic and immunohistochemical stain characteristics are disparate. Its rarity and the wide spectrum of clinical behavior combined with the lack of sensitivity of serum levels of beta hCG in predicting disease recurrence and spread have lead to anecdotal reports outlining clinical management. Most discerning to the clinician is the high mortality of metastatic placental site trophoblastic tumor. At our institution, we have treated two patients with a metastatic disease with a successful conclusion. The durability of responses is 3 and 8 years. This report will present these patients in detail and define the important characteristics of successful treatment. The use of dose-intensive, multi-agent chemotherapy, early intervention when metastatic disease is discovered, imaging techniques to define disease spread, surgery for localized disease and the use of growth factors, most notably granulocyte colony-stimulating factor (G-CSF), are the fundamentals of clinical care of placental site trophoblastic tumor in patients with metastatic placental site trophoblastic tumor.

KW - Malignant trophoblastic disease

KW - Placental site trophoblastic tumor

KW - Trophoblastic disease

KW - Trophoblastic pseudotumor

UR - http://www.scopus.com/inward/record.url?scp=0002134342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002134342&partnerID=8YFLogxK

M3 - Article

C2 - 9833615

AN - SCOPUS:0002134342

VL - 60

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - SUPPL.1

ER -